Lazard Asset Management LLC Purchases 25,109 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Lazard Asset Management LLC boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 644.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 29,006 shares of the company's stock after purchasing an additional 25,109 shares during the quarter. Lazard Asset Management LLC's holdings in Elanco Animal Health were worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in ELAN. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $29,000. Jones Financial Companies Lllp boosted its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. boosted its position in shares of Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares in the last quarter. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $61,000. Finally, Blue Trust Inc. increased its position in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after buying an additional 1,894 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $10.90 per share, with a total value of $109,000.00. Following the completion of the transaction, the director now directly owns 101,459 shares in the company, valued at $1,105,903.10. This represents a 10.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.89% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Stifel Nicolaus boosted their target price on Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Monday, May 19th. UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Elanco Animal Health currently has an average rating of "Hold" and a consensus price target of $15.17.

Elanco Animal Health Stock Down 0.1%

Shares of ELAN stock traded down $0.02 during trading on Wednesday, reaching $13.17. The company's stock had a trading volume of 1,243,191 shares, compared to its average volume of 5,069,378. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.80. The business has a fifty day moving average price of $10.43 and a 200-day moving average price of $11.43. The company has a market cap of $6.54 billion, a price-to-earnings ratio of 32.91, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.06. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue for the quarter was down 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.34 EPS. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.